The aim of this study was to determine whether calcium potentiates acute carbon tetrachloride (CCl4) -induced toxicity. Elevated calcium levels were induced in mice by pre-treatment with cholecalciferol (vitamin D3; V.D3), a compound that has previously been shown to induce hypercalcemia in human and animal models. As seen previously, mice injected with CCl4 exhibited increased plasma levels of alanine aminotransferase, aspartate aminotransferase, and creatinine; transient body weight loss; and increased lipid peroxidation along with decreased total antioxidant power, glutathione, ATP, and NADPH. Pre-treatment of these animals with V.D3 caused further elevation of the values of these liver functional markers without altering kidney functional markers; continued weight loss; a lower lethal threshold dose of CCl4; and enhanced effects on lipid peroxidation and total antioxidant power. In contrast, exposure to V.D3 alone had no effect on plasma markers of liver or kidney damage or on total antioxidant power or lipid peroxidation. The potentiating effect of V.D3 was positively correlated with elevation of hepatic calcium levels. Furthermore, direct injection of CaCl2 also enhanced CCl4-induced hepatic injury. Since CaCl2 induced hypercalcemia transiently (within 3 h of injection), our results suggest that calcium enhances the CCl4-induced hepatotoxicity at an early stage via potentiation of oxidative stress.
Citation: Yoshioka H, Usuda H, Miura N, Fukuishi N, Nonogaki T, Onosaka S (2017) Vitamin D3-induced hypercalcemia increases carbon tetrachloride-induced hepatotoxicity through elevated oxidative stress in mice. PLoS ONE 12(4): e0176524. https://doi.org/10.1371/journal.pone.0176524
Editor: Matias A. Avila, University of Navarra School of Medicine and Center for Applied Medical Research (CIMA), SPAIN
Received: February 8, 2017; Accepted: April 12, 2017; Published: April 27, 2017
Copyright: © 2017 Yoshioka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate amino transferase; CCl4, carbon tetrachloride; V.D3, vitamin D3; ATP, adenosine triphosphate; NADPH, reduced nicotinamide adenine dinucleotide phosphate
Carbon tetrachloride (CCl4) is widely used in experimental animal models of liver failure that mimic human hepatic toxicity. The mechanism of CCl4 hepatotoxicity has been thoroughly studied since 1967, including the use of in vivo models of acute and chronic CCl4 poisoning, ex vivo perfusion of livers, and the use of isolated or cultured hepatocytes [1, 2]. CCl4-induced toxicity is a multifactorial process involving the generation of CCl4-derived free radicals [2–5]. The first step is metabolic activation of CCl4 by CYP2E1, whereby CCl4 is converted to free radicals (trichloromethyl and trichloromethyl peroxy radicals). The second step is binding of these radicals to antioxidant enzymes, including the sulfhydryl (protein thiol) groups of glutathione (GSH). In the third step, these overproduced free radicals increase membrane lipid peroxidation, bind covalently to macromolecules, deplete ATP, and interfere with calcium homeostasis [6–8]. Since sulfhydryl groups are essential elements of the molecular arrangements responsible for the Ca2+ transport across cellular membranes, loss of function of these proteins is expected to impair the capacity of microsomes and mitochondria to regulate cellular calcium levels.
Recently, we found that cadmium (Cd) -induced cell cytotoxicity is attenuated by calcium-free medium in vitro (unpublished data). These data suggest that calcium is directly involved in Cd-induced toxicity. Because Cd-related toxicity is mediated by GSH depletion, lipid peroxidation, and mitochondrial dysfunction [9–11] (that is, by processes similar to those of CCl4-induced toxicity), we hypothesized that calcium might also exacerbate CCl4 toxicity.
It is well known that some drugs (e.g., thiazide diuretics) cause hypercalcemia [12, 13]. Treatment with vitamin D commonly has been used to investigate hypercalcemia in animal models [14–16]. In calcium homeostasis, vitamin D3 (V.D3) is a potent serum calcium-raising agent that regulates both calcitonin (CT) and parathyroid hormone (PTH) gene expression [17–19]. Serum calcium is the major secretagogue for CT, a hormone product whose biosynthesis is the main biological activity of thyroid C-cells. Taking advantage of this regulatory mechanism, vitamin D3-induced hypercalcemia has been extensively used.
Therefore, in the current study, we investigated whether hypercalcemic mice exhibited increased CCl4-induced toxicity. To examine the effect of calcium on acute CCl4 toxicity, we pre-treated animals with V.D3, before determining plasma biochemical markers, hepatic lipid peroxidation, and hepatic calcium levels.
Material and methods
Male ddY mice were purchased from Japan SLC (Hamamatsu, Japan) and were maintained under standard conditions of controlled temperature (24 ± 1°C), humidity (55 ± 5%), and light (12:12 h light/dark cycles) with free access to water and food. Experimental treatments were performed using eight-week-old animals. Following the experiment, any surviving mice were sacrificed using pentobarbital. All experiments were approved by the Institutional Animal Care and Experiment Committee of Kinjo Gakuin University (No. 110).
Evaluation of the effect of vitamin D3 on CCl4 toxicity
Mice were divided into two groups (olive oil + CCl4 and V.D3 + CCl4) of twelve mice each. On Days -4 to -1 (i.e., each of the four days prior to CCl4 injection), animals were administered once daily (at 24-h intervals) by oral gavage (per os; p.o.) with cholecalciferol (vitamin D3; V.D3; Tokyo Chemical Industry, Tokyo, Japan; formulated in olive oil (Nacalai Tesque, Kyoto, Japan)) at 5 mg/kg, or with an equivalent volume of olive oil vehicle alone. On the nominal Day 0 (i.e., twenty-four hours after the final gavage), each mouse was injected intraperitoneally (i.p.) with CCl4 (Wako Chemical, Osaka, Japan) at 2 g/kg (5 mL/kg). Before the CCl4 injection, we collected pre-dose blood samples from each mouse; these specimens were used to confirm the effects of V.D3 on plasma Ca concentrations. At 24 h after the CCl4 injection, three randomly selected mice from each group were euthanized; livers were harvested from each of these animals and flash frozen for storage at -80°C. The remaining mice (nine per group) were maintained on study through Day 7. Once daily following CCl4 injection, animals were checked for mortality and body weight was recorded. Additionally, on Days 1, 3, and 7, remaining animals were subjected to blood sampling for determination of blood functional markers. Following the Day-7 procedures, any surviving mice were sacrificed using pentobarbital. Experimental procedure is described in Fig 1.
Evaluation of role of calcium in CCl4 toxicity
Mice were divided into three groups (Ca + olive oil, saline + CCl4, and Ca + CCl4) of six mice each. Animals were administered i.p. with calcium chloride (CaCl2: Wako Chemical; formulated in physiological saline) at 150 mg/kg or with an equivalent volume of saline vehicle. Ten minutes later, animals were administered i.p. with CCl4 at 2 g/kg or with an equivalent volume of olive oil. Whole blood was collected at 10 and 30 min and at 1, 3, 6, 12, and 24 h (the last by terminal bleed) after CaCl2 injection. At each time point, whole blood specimens were centrifuged (3000× g, 10 min), and the plasma supernatants were frozen and stored at -80°C pending use for determination of plasma calcium concentrations (all time points) or hepatic injury markers (terminal samples). Following the terminal bleeds (at 24 h after i.p. injections), mice of each group were euthanized and livers were harvested. Liver specimens were flash-frozen and stored at -80°C pending use for determination of hepatic calcium levels.
Plasma biochemical analysis
Plasma calcium levels were measured using the calcium-E test (Wako Chemical) according to the manufacturer’s instructions. Plasma sample (2.5 μL) was mixed with substrate buffer (100 μL) and coloring reagent (50 μL). The absorbance of the reaction mixture was measured at 610 nm.
Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were measured using the Transaminase CII Test Wako (Wako Chemical) according to the manufacturer’s instructions and as previously described [20, 21]. Concentrations of plasma creatinine and blood urea nitrogen (BUN) were measured using Creatinine Liquid Reagents Assay (DIAZYME, Poway, CA) and BUN Wako Test (Wako Chemical), respectively, according to the manufacturer’s instructions and as previously described [22, 23]. For relative quantification, calibration curves were prepared using standard solutions.
Isolation of total RNA and qRT-PCR assay
Total RNA was extracted from 0.1 g liver sections using the ISOGEN II kit (Nippon Gene, Tokyo, Japan). qRT-PCR was performed with One Step SYBR PrimeScript PLUS RT-PCR kit (Perfect Real Time) (Takara Bio, Shiga, Japan) using an Applied Biosystems 7300 system (Applied Biosystems, Foster City, CA). PCR conditions were as previously described . Primer pairs are shown in Table 1. Relative expression of each mRNA was determined using the standard curve method. The amount of each target mRNA quantified was normalized against that of GAPDH-encoding mRNA.
For histological analysis, a portion of the left liver lobe from each animal were perfused with 15% phosphate-buffered neutral formalin (pH 7.2), dehydrated, and embedded in paraffin. Embedded tissues were sectioned at 4 μm and stained with hematoxylin and eosin (H&E), Masson trichrome (MT), or von Kossa. MT stain kit and von Kossa stain were purchased from ScyTek Laboratories, Inc. (Logan, UT, USA) and conducted accordance with manufacture’s instructions. Histopathological features were observed using a light microscope.
Measurement of malondialdehyde levels in the liver
The total malondialdehyde (MDA) levels and total antioxidant power in the liver were examined by colorimetric microplate assay (Oxford Biochemical Research, Oxford, MI) according to the manufacturer's protocol and as previously described [22, 23].
Determination of glutathione (GSH) levels in the liver
Hepatic GSH levels were measured using GSSG/GSH quantification kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer’s instructions and as previously described .
Measurement of ATP and NADPH levels in the liver
Hepatic ATP and NADPH levels were measured using ATP Colorimetric / Fluorometric Assay kit (BioVision, Inc., Mountain View, CA, USA) and NADH/NADPH Assay kit (BioAssay Systems, Hayward, CA, USA), respectively. These tests were conducted accordance with manufacture’s instructions.
Determination of liver calcium concentrations
Individual liver specimens (0.2–0.3 g each) were digested in 0.5 mL of concentrated nitric acid in glass test tubes. The temperature was held at 80°C for 1 h, then gradually increased (at 10°C per h) to 130°C. When the acid-digested specimens became transparent, volumes of the digests were raised to 5 mL with distilled water, and calcium concentrations were determined by atomic absorption using a Z-2300 (Hitachi, Tokyo, Japan).
All data from the control and treatment groups were obtained from the same numbers of replicated experiments. All experiments were performed independently at least two times. Two-group comparisons were made using Student’s t-test or Welch’s t-test; multiple comparisons were analyzed using One-Way ANOVA with post-hoc Tukey-Kramer’s test. Tests were two-tailed. The results of the survival tests were analyzed by means of χ2 analysis. All statistical analyses were performed using SPSS 19.0J software (Chicago, IL). Values of P < 0.05 were considered statistically significant.
Effect of pre-treatment with V.D3 on CCl4 acute toxicity, as assessed by body weight and mortality
To determine the effects of V.D3 pre-treatment, we performed analysis of plasma biochemical markers. Four-time, once-daily pre-treatment with V.D3 significantly increased plasma Ca concentrations to 13.0 mg/dL compared to the control value of 7.7 mg/dL (Table 2); these elevated levels would be classified as severe hypercalcemia. In contrast, plasma levels of ALT and AST (markers of hepatic injury; Fig 2) and of creatinine and BUN (markers of kidney injury; Fig 3) were comparable between V.D3- and olive oil-treated groups.
Mice were pre-treated with olive oil (vehicle) or with V.D3 (at 5 mg/kg) administered as four once-daily p.o. doses. At 24 h after the final pre-treatment, mice of both groups were injected i.p. with CCl4 (at 2 g/kg). Plasma ALT (A) and AST (B) activities were determined at 0, 1, 3, and 7 days after CCl4 injection. Data are presented as mean ± S.D. of 4–9 mice. # P < 0.05, ## P < 0.01 versus CCl4 group on the respective day.
Mice were treated as described in legend for Fig 2. Plasma creatinine (A) and BUN (B) levels were determined at 0, 1, 3, and 7 days after CCl4 injection. Data are presented as mean ± S.D. of 4–9 mice.
These pre-treated animals were administered i.p. with CCl4 at 2 g/kg. Animals pre-treated with olive oil (instead of V.D3) and then injected with CCl4 exhibited a transient loss of approximately 10% body weight on the first day and subsequent recovery from Day 2 (Fig 4A). In contrast, weight loss in the hypercalcemic mice (pre-treated with V.D3) continued in the days following CCl4 injection, achieving approximately 30% loss of weight by Day 7 (compared to baseline), a change that was significant compared to that in the control group. In addition, mortality was significantly elevated in the V.D3 + CCl4 treatment group compared to the control animals (Fig 4B). Notably, none of the mice died following CCl4 injection, while 55.6% (5 of 9; 4 on Day 2 and 1 on Day 7) of the hypercalcemic mice were found dead in the week following CCl4 injection.
Mice were treated as described in legend for Fig 2. Body weights (normalized to baseline) (A) and mortality (B) were recorded every 24 h through the 7th day after CCl4 injection. Data are presented as mean ± S.D. of 4–9 mice. ## P < 0.01 versus CCl4 group on the respective day.
Changes in hepatic and renal injury markers in CCl4-exposed mice pre-treated with V.D3
To reveal the target organ of CCl4-induced toxicity under hypercalcemic conditions, we next examined hepatic injury markers in the CCl4-treated mice. As shown in Fig 2, pre-treatment with V.D3 significantly potentiated the increase in plasma ALT and AST levels seen following CCl4 injection; these parameters recovered by the 7th day after CCl4 injection.
In parallel with the measurement of ALT and AST, we evaluated plasma creatinine and BUN levels, which are markers of renal injury. As shown in Fig 3A, CCl4 exposure yielded significant increases (in both groups) in creatinine levels at Days 1 and 3 (compared to respective baseline values), but these effects did not differ significantly between groups (i.e., for animals pre-treated with V.D3 rather than olive oil). On the other hand, although CCl4 exposure yielded an increase (compared to baseline) in Day-1 BUN in animals pre-treated with V.D3, this effect was not significant (at any of the time points) compared to the values obtained with animals pre-treated with olive oil (Fig 3B).
Effect of pre-treatment with V.D3 on CCl4 acute toxicity, as assessed by hepatic CYP2E1 levels
In addition to plasma injury markers, we measured hepatic CYP2E1 mRNA levels since CYP2E1 is a major CYP contribution to CCl4 activation . As shown in Fig 5, CCl4 exposure indicated significant decreases (in both groups) at Days 1 and 3. On the other hand, although CCl4 treated group at Day 7 was recovered in CYP2E1, V.D3 + CCl4 group was maintained at low level. Moreover, control and VD.3 group at all days were no significant change in CYP2E1 levels.
Effect of pre-treatment with V.D3 on CCl4 acute toxicity, as assessed by MT stain
Next, we conducted Masson Trichrome stain since CCl4 is well known to induce liver fibrosis [27, 28]. However, hepatic fibrosis was not observed in all groups (Fig 6), suggests generation of hepatic fibrosis need to inject multiple times.
Animals were treated as described in legend for Fig 2, and livers were harvested at 24 h, 72 h, or 168 h after CCl4 injection. Liver specimens were fixed and stained with MT. Micrographs provide 10× magnified images of representative MT-stained liver sections obtained from the control (A), V.D3 (B), CCl4 (C), and V.D3 + CCl4 (D) groups at Day 1, control (E), V.D3 (F), CCl4 (G), and V.D3 + CCl4 (H) groups at Day 3, control (I), V.D3 (J), CCl4 (K), and V.D3 + CCl4 (L) groups at Day 7, respectivity.
Changes in morphology, MDA, total antioxidant levels, ATP, and NADPH levels in CCl4-exposed mice pre-treated with V.D3
To further investigate V.D3-induced exacerbation of liver damage, we randomly selected mice from each group, harvested livers from these animals at 24 h after CCl4 treatment, and conducted histopathological studies. H&E-stained liver sections from the control and V.D3 groups showed a normal cell morphology and well-preserved cytoplasm, in addition to a clear, plump nucleus (Fig 7A and 7B). In contrast, we observed necrosis in the mice treated with CCl4 (Fig 7C). In addition, Pretreatment with V.D3 become exacerbated some, but not all, liver cell necrosis (Fig 7D).
Mice were treated as described in legend for Fig 2. At 24 h after CCl4 injection, animals were euthanized and livers were harvested at necropsy. Liver specimens were fixed and processed by standard methods, and sections were stained with H&E (A–D). Micrographs provide 10× magnified images of representative H&E-stained liver sections obtained from the control (A), V.D3 (B), CCl4 (C), and V.D3 + CCl4 (D) groups. Black arrows indicate area of necrosis.
In parallel with histopathological studies, we measured liver MDA levels as a marker of lipid peroxidation. CCl4 treatment significantly increased hepatic MDA levels, both in animals pre-treated with olive oil and in those pre-treated with V.D3 (Fig 8A). Pre-treatment with V.D3 further potentiated the CCl4-induced increase in MDA levels (CCl4 vs. V.D3 + CCl4).
Mice were treated as described in legend for Fig 2. At 24 h after CCl4 injection, animals were euthanized and livers were collected for determination of MDA levels (A), total antioxidant power (B), hepatic ATP levels (C), and hepatic NADPH levels (D). Data are presented as mean ± S.D. of 6 mice. * P < 0.05 and ** P < 0.01 versus control, # P < 0.05 and ## P < 0.01 versus CCl4 group.
Many studies have suggested that total antioxidant power, ATP, and NADPH can be used as an indicator of oxidative stress. As shown in Fig 8B, CCl4-treatment markedly decreased the total antioxidant power, and pre-treatment with V.D3 potentiated the CCl4-induced decrease in antioxidant power. Notably, for both hepatic MDA and total oxidant power, values did not differ significantly between animals pre-treated with vehicle and with V.D3. This observation demonstrated that hypercalcemia itself does not induce either of these parameters. In addition, hepatic ATP and NAPDH levels were consistent with total antioxidant power (Fig 8C and 8D).
Moreover, we determined hepatic GSH levels, that is well known to deplete on CCl4 administration [29–32]. As shown in Fig 9A, CCl4 treatment significantly decreased hepatic GSH levels, both in animals pre-treated with olive oil and in those pre-treated with V.D3. Pre-treatment with V.D3 further potentiated the CCl4-induced decrease in GSH levels (CCl4 vs. V.D3 + CCl4). Moreover, we determined glutamate cysteine ligase catalytic subunit (GCLC) and glutamate cysteine ligase modifier subunit (GCLM) by qRT-PCR assay (Fig 9B and 9C). Although GCLC was same tendency compared with GSH, GCLM was no significant change in all groups in the present study.
Mice were treated as described in legend for Fig 2. At 24 h after CCl4 injection, animals were euthanized and livers were collected for determination of GSH levels (A), GCLC mRNA (B), and GCLM mRNA (C). Data are presented as mean ± S.D. of 6 mice. * P < 0.05 and ** P < 0.01 versus control, # P < 0.05 and ## P < 0.01 versus CCl4 group.
Influence of V.D3 on CCl4 acute toxicity as assessed by hepatic calcium levels and calcium stain
As we showed above, pre-treatment with V.D3 yielded increased plasma Ca levels. We next examined whether V.D3 pre-treatment, with or without CCl4 exposure, also altered hepatic calcium levels at 24 h post CCl4 injection, which we assessed by atomic absorption spectrometry (Fig 10A). In animals pre-treated with olive oil, CCl4 injection yielded a significant, 60-fold increase in liver Ca levels. Injection of CCl4 in mice pre-treated with V.D3 yielded a further >3-fold elevation in hepatic Ca levels. Notably, pre-treatment with V.D3 yielded a small (1.8-fold) and non-significant increase in hepatic Ca levels compared to pre-treatment with olive oil (in the absence of CCl4 injection). This observation demonstrated that V.D3 alone does not induce appreciable hypercalcemia of the liver. In further to investigate Ca involvement, we stained hepatic Ca by von Kossa method. In control and V.D3 groups, Ca deposition was not observed (Fig 10B and 10C). In contrast, Injection of CCl4 in mice was slightly confirmed von Kossa positive staining in the area necrosis is not observed (Fig 10D). Moreover, maximum von Kossa staining was confirmed in V.D3 + CCl4 group (Fig 10E).
Animals were treated as described in legend for Fig 2, and livers were harvested at 24 h after CCl4 injection. (A): Hepatic calcium levels at 24 h were determined by atomic absorption spectrometry. Data are presented as mean ± S.D. of 6 mice. * P < 0.05 and ** P < 0.01 versus control, ## P < 0.01 versus CCl4 group. (B–E): Liver specimens were fixed and stained with von Kossa. Micrographs provide 10× magnified images of representative von Kossa-stained liver sections obtained from the control (B), V.D3 (C), CCl4 (D), and V.D3 + CCl4 (E) groups.
Direct assessment of Ca effect on CCl4 acute toxicity
In order to confirm the involvement of calcium in CCl4 toxicity, we induced hypercalcemia by direct injection of CaCl2 and monitored plasma calcium levels for the subsequent 24 h, both with and without concomitant CCl4 exposure. As shown in Fig 11B, i.p. injection of CaCl2 induced transient (within 3 h) hypercalcemia. When mice with this evanescent hypercalcemia were injected with CCl4 (Ca + CCl4), the animals exhibited significantly elevated plasma ALT and AST levels and hepatic calcium levels compared to normal-calcemic mice (CCl4) (Table 3).
Mice were injected i.p. with CaCl2 at 150 mg/kg. Plasma calcium levels were determined after 10 and 30 min and at 1, 3, 6, 12, and 24 h after CaCl2 injection. (A) and (B) show the schematic experimental design of CaCl2 injection and the results, respectively. Data are presented as mean ± S.D. of 6 mice.
The present study demonstrated that pre-treatment with V.D3 potentiated CCl4-induced hepatotoxicity and enhanced mouse mortality, without increasing renal toxicity and generation of liver fibrosis. Our previous investigation demonstrated that single i.p. injection of mice with a fatal dose of CCl4 (4 g/kg) induced severe hepatotoxicity and moderate renal toxicity [20, 22, 24]; however, the critical target organ that led to mouse death following CCl4 injection was not defined. In the current study, V.D3 potentiation of toxicity was observed only in the liver, as indicated by plasma levels of ALT and AST, biochemical markers of hepatic damage. Although pre-treatment with V.D3 significantly increased renal calcium levels compared to those in animals pre-treated with olive oil, renal calcium content did not differ significantly between mice treated with olive oil + CCl4 and those treated with V.D3 + CCl4 (data not shown). Together, these data suggest that the liver is the primary target organ of acute CCl4 toxicity.
CCl4 is metabolized and activated by multiple CYPs, including CYP2E1, CYP2B1, and CYP2B2 . In particular, CYP2E1 is a major CYP contribution to CCl4 activation . Several literatures reported pre-treatment with phenobarbital, acarbose, or natural products (such as Salvia officinalis) have been shown to potentiate the CYP2E1-mediated hepatotoxicity of CCl4 [33–36]. Although vitamin D is known to induce the expression of CYP3A and CYP2B6 via activation of the vitamin D receptor (VDR), the pregnane X receptor (PXR), and/or the constitutive androstane receptor (CAR) [37–39], we are not aware of any reports of V.D3-induced expression of CYP2E1, 2B1, or 2B2. In fact, hepatic CYP2E1 expression level was not changed by pretreatment with V.D3. Taken together, these observations indicate that CYPs are not primary mediators of the V.D3 potentiation of CCl4 toxicity.
Several studies suggest that a possible molecular mechanism involved in CCl4 hepatotoxicity is the disruption of the delicate oxidant/antioxidant balance, which can lead to liver injury via oxidative damage [2, 40]. Our results suggest that V.D3 (or a V.D3-induced factor) triggers an enhancement of CCl4-induced toxicity. Since V.D3 has no ability to change every parameters such as antioxidant power, MDA levels, ATP levels, NADPH levels, GSH levels, and GCL subunit levels, V.D3 itself is not an oxidant. We hypothesize that calcium is likely the aggravating factor, given that pre-treatment with CaCl2 yielded potentiation of CCl4 toxicity similar to that seen with pre-treatment with V.D3, a compound known to induce hypercalcemia. In addition, the extracellular plasma calcium concentration is tightly controlled by a complex homeostatic mechanism involving fluxes of calcium between the extracellular fluid and the kidneys, bones, and hormones. It has been reported that CCl4 disrupts hepatic calcium homeostasis [41, 42]. In the current study, CCl4-induced hepatic calcium levels were increased by pre-treatment with V.D3, indicating that calcium is a candidate aggravating factor of CCl4 toxicity. Moreover, multiple researchers have reported that CCl4 significantly decreases the total content of reduced GSH, and that CCl4-derived radicals can react with sulfhydryl groups of GSH and other protein thiols [29–32]. Our data also supports these reports since GSH was depleted by CCl4 and these depletion levels got worse by pretreatment with V.D3. In addition, GSH is sequentially synthesize catalytic subunit d from glutamate, cysteine, and glycine, which is mainly controlled by GCL. GCL is composed of two subunits, the GCLC and the modifier subunit GCLM. Our study indicated that GCLC was same tendency compared with GSH. In contrast, GCLM was no significant change in all groups in the present study. These data suggests that single injection of CCl4 might attack GCLC rather than GCLM since multiple injection of CCl4 reduces both parameters .
Since some protein thiols are essential components of the molecular rearrangements that are required for Ca2+ transport across cell membranes, loss of such thiols may affect the calcium sequestration activity of subcellular compartments; mitochondria and microsomes employ this sequestration to regulate cytosolic calcium levels. Hence, pre-treatment with V.D3 might induce the collapse of these cellular functions by disrupting calcium homeostasis in the cell.
We demonstrated that both V.D3-induced hypercalcemia and direct injection of calcium itself potentiate CCl4-induced toxicity; these results suggest that calcium potentiates hepatotoxicity. In addition, we speculate that calcium augments the CCl4-induced toxicity within several hours after CCl4-injection, given that transient hypercalcemia was observed at the earliest time points following CaCl2 injection . It has been reported that CCl4-induced hepatotoxicity occurs within 3 h of exposure , consistent with our speculation.
In conclusion, we demonstrated that V.D3-induced hypercalcemia or pre-treatment with CaCl2 enhances CCl4-induced hepatotoxicity, presumably via disruption of calcium homeostasis. To our knowledge, this is the first evidence that calcium enhances CCl4-induced hepatotoxicity in the early stage in mice. These findings may have relevance to the mechanism of toxicity of other hepatotoxic compounds.
The authors thank Dr. Kenichi Saeki (Kinjo Gakuin University, Japan) for his kind suggestions.
- Conceptualization: HY HU SO.
- Data curation: HY TN.
- Formal analysis: HY TN.
- Funding acquisition: NM NF.
- Investigation: HY TN.
- Methodology: HY.
- Project administration: HY SO.
- Resources: HY.
- Software: HY HU TS SO.
- Supervision: HY.
- Validation: HY.
- Visualization: HY.
- Writing – original draft: HY.
- Writing – review & editing: HY HU.
- 1. Recknagel RO. Carbon tetrachloride hepatotoxicity. Pharmacol Rev. 1967;19(2):145–208. Epub 1967/06/01. pmid:4859860
- 2. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003;33(2):105–36. Epub 2003/04/24. pmid:12708612
- 3. Recknagel RO, Glende EA Jr., Dolak JA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther. 1989;43(1):139–54. Epub 1989/01/01. pmid:2675128
- 4. Wong FW, Chan WY, Lee SS. Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol. 1998;153(1):109–18. Epub 1999/01/06. pmid:9875305
- 5. Manibusan MK, Odin M, Eastmond DA. Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2007;25(3):185–209. Epub 2007/09/01. pmid:17763046
- 6. Tyson CA, Story DL, Stephens RJ. Ultrastructural changes in isolated rat hepatocytes exposed to different CCl4 concentrations. Biochem Biophys Res Commun. 1983;114(2):511–7. Epub 1983/07/29. pmid:6882440
- 7. Brattin WJ, Pencil SD, Waller RL, Glende EA Jr., Recknagel RO. Assessment of the role of calcium ion in halocarbon hepatotoxicity. Environ Health Perspect. 1984;57:321–3. Epub 1984/08/01. PubMed Central PMCID: PMC1568267. pmid:6499814
- 8. Berger ML, Reynolds RC, Combes B. Carbon tetrachloride-induced morphologic alterations in isolated rat hepatocytes. Exp Mol Pathol. 1987;46(3):245–57. Epub 1987/06/01. pmid:3595801
- 9. Brady JF, Xiao F, Wang MH, Li Y, Ning SM, Gapac JM, et al. Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats. Toxicol Appl Pharmacol. 1991;108(2):366–73. Epub 1991/04/01. pmid:1850173
- 10. El-Demerdash FM, Yousef MI, Kedwany FS, Baghdadi HH. Cadmium-induced changes in lipid peroxidation, blood hematology, biochemical parameters and semen quality of male rats: protective role of vitamin E and beta-carotene. Food Chem Toxicol. 2004;42(10):1563–71. Epub 2004/08/12. pmid:15304303
- 11. Sarkar S, Yadav P, Trivedi R, Bansal AK, Bhatnagar D. Cadmium-induced lipid peroxidation and the status of the antioxidant system in rat tissues. J Trace Elem Med Biol. 1995;9(3):144–9. Epub 1995/10/01. pmid:8605602
- 12. Parfitt AM. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med. 1969;281(2):55–9. Epub 1969/07/10. pmid:5305802
- 13. Desai HV, Gandhi K, Sharma M, Jennine M, Singh P, Brogan M. Thiazide-induced severe hypercalcemia: a case report and review of literature. Am J Ther. 2010;17(6):e234–6. Epub 2010/01/14. pmid:20068444
- 14. Zhou JY, Norman AW, Chen DL, Sun GW, Uskokovic M, Koeffler HP. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci U S A. 1990;87(10):3929–32. Epub 1990/05/01. PubMed Central PMCID: PMC54017. pmid:2339131
- 15. Tsuruoka S, Sugimoto K, Fujimura A. Contribution of diet to the dosing time-dependent change of vitamin D3-induced hypercalcemia in rats. Life Sci. 2000;68(5):579–89. Epub 2001/02/24. pmid:11197755
- 16. Nishiki K, Tsuruoka S, Wakaumi M, Yamamoto H, Koyama A, Fujimura A. Dosing time-dependent variation in the hypocalcemic effect of calcitonin in rat. Eur J Pharmacol. 2003;460(2–3):171–5. Epub 2003/02/01. pmid:12559378
- 17. Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006;92(1):4–8. Epub 2006/03/28. pmid:16563471
- 18. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013;87(8):1315–530. Epub 2013/08/27. PubMed Central PMCID: PMC3753504. pmid:23974980
- 19. Han YP, Kong M, Zheng S, Ren Y, Zhu L, Shi H, et al. Vitamin D in liver diseases: from mechanisms to clinical trials. J Gastroenterol Hepatol. 2013;28 Suppl 1:49–55. Epub 2013/07/24.
- 20. Yoshioka H, Usuda H, Nonogaki T, Onosaka S. Carbon tetrachloride-induced lethality in mouse is prevented by multiple pretreatment with zinc sulfate. J Toxicol Sci. 2016;41(1):55–63. Epub 2016/01/15. pmid:26763393
- 21. Yoshioka H, Tanaka M, Fujii H, Nonogaki T. Sasa veitchii extract suppresses carbon tetrachloride-induced hepato- and nephrotoxicity in mice. Environ Health Prev Med. 2016;21(6):554–62. Epub 2016/10/16. PubMed Central PMCID: PMC5112209. pmid:27738877
- 22. Yoshioka H, Usuda H, Fukuishi N, Nonogaki T, Onosaka S. Carbon Tetrachloride-Induced Nephrotoxicity in Mice Is Prevented by Pretreatment with Zinc Sulfate. Biol Pharm Bull. 2016;39(6):1042–6. Epub 2016/06/03. pmid:27251508
- 23. Yoshioka H, Fukaya S, Fukuishi N, Nagatsu A, Nonogaki T, Onosaka S. Bromobenzene-induced lethal toxicity in mouse is prevented by pretreatment with zinc sulfate. Chem Biol Interact. 2016;254:117–23. Epub 2016/06/09. pmid:27270452
- 24. Yoshioka H, Onosaka S. Zinc sulfate pretreatment prevents carbon tetrachloride-induced lethal toxicity through metallothionein-mediated suppression of lipid peroxidation in mice. Fundam Toxicol Sci. 2016;3(4):151–6.
- 25. Miura N, Ashimori A, Takeuchi A, Ohtani K, Takada N, Yanagiba Y, et al. Mechanisms of cadmium-induced chronotoxicity in mice. J Toxicol Sci. 2013;38(6):947–57. Epub 2013/11/29. pmid:24284284
- 26. Yoshioka H, Nonogaki T, Fukuishi N, Onosaka S. Calcium-deficient diet attenuates carbon tetrachloride-induced hepatotoxicity in mice through suppression of lipid peroxidation and inflammatory response. Heliyon. 2016;2(6):e00126. Epub 2016/07/22. PubMed Central PMCID: PMC4946292. pmid:27441297
- 27. Shrestha N, Chand L, Han MK, Lee SO, Kim CY, Jeong YJ. Glutamine inhibits CCl4 induced liver fibrosis in mice and TGF-beta1 mediated epithelial-mesenchymal transition in mouse hepatocytes. Food Chem Toxicol. 2016;93:129–37. Epub 2016/05/04. pmid:27137983
- 28. Cui X, Dang S, Wang Y, Chen Y, Zhou J, Shen C, et al. Retinol dehydrogenase 13 deficiency diminishes carbon tetrachloride-induced liver fibrosis in mice. Toxicol Lett. 2017;265:17–22. Epub 2016/11/21. pmid:27865848
- 29. Sheweita SA, Abd El-Gabar M, Bastawy M. Carbon tetrachloride-induced changes in the activity of phase II drug-metabolizing enzyme in the liver of male rats: role of antioxidants. Toxicology. 2001;165(2–3):217–24. Epub 2001/08/28. pmid:11522380
- 30. Khan MR, Rizvi W, Khan GN, Khan RA, Shaheen S. Carbon tetrachloride-induced nephrotoxicity in rats: protective role of Digera muricata. J Ethnopharmacol. 2009;122(1):91–9. Epub 2009/01/03. pmid:19118616
- 31. Khan RA, Khan MR, Sahreen S, Bokhari J. Prevention of CCl4-induced nephrotoxicity with Sonchus asper in rat. Food Chem Toxicol. 2010;48(8–9):2469–76. Epub 2010/06/17. pmid:20550952
- 32. Rivera H, Shibayama M, Tsutsumi V, Perez-Alvarez V, Muriel P. Resveratrol and trimethylated resveratrol protect from acute liver damage induced by CCl4 in the rat. J Appl Toxicol. 2008;28(2):147–55. Epub 2007/06/02. pmid:17541932
- 33. Wang PY, Kaneko T, Wang Y, Sato A. Acarbose alone or in combination with ethanol potentiates the hepatotoxicity of carbon tetrachloride and acetaminophen in rats. Hepatology. 1999;29(1):161–5. Epub 1998/12/24. pmid:9862862
- 34. Lima CF, Fernandes-Ferreira M, Pereira-Wilson C. Drinking of Salvia officinalis tea increases CCl(4)-induced hepatotoxicity in mice. Food Chem Toxicol. 2007;45(3):456–64. Epub 2006/11/07. pmid:17084954
- 35. Head B, Moody DE, Woo CH, Smuckler EA. Alterations of specific forms of cytochrome P-450 in rat liver during acute carbon tetrachloride intoxication. Toxicol Appl Pharmacol. 1981;61(2):286–95. Epub 1981/11/01. pmid:7324070
- 36. Klingensmith JS, Mehendale HM. Potentiation of CCl4 lethality by chlordecone. Toxicol Lett. 1982;11(1–2):149–54. Epub 1982/04/01. pmid:6178186
- 37. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277(28):25125–32. Epub 2002/05/07. pmid:11991950
- 38. Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013;136:54–8. Epub 2012/09/19. PubMed Central PMCID: PMC3549031. pmid:22985909
- 39. Larriba MJ, Gonzalez-Sancho JM, Bonilla F, Munoz A. Interaction of vitamin D with membrane-based signaling pathways. Front Physiol. 2014;5:60. Epub 2014/03/07. PubMed Central PMCID: PMC3927071. pmid:24600406
- 40. Hsouna AB, Saoudi M, Trigui M, Jamoussi K, Boudawara T, Jaoua S, et al. Characterization of bioactive compounds and ameliorative effects of Ceratonia siliqua leaf extract against CCl(4) induced hepatic oxidative damage and renal failure in rats. Food Chem Toxicol. 2011;49(12):3183–91. Epub 2011/10/15. pmid:21996303
- 41. Lowrey K, Glende EA Jr., Recknagel RO. Destruction of liver microsomal calcium pump activity by carbon tetrachloride and bromotrichloromethane. Biochem Pharmacol. 1981;30(2):135–40. Epub 1981/01/15. pmid:7236302
- 42. Recknagel RO, Lowrey K, Waller RL, Glende EA Jr. Destruction of microsomal calcium pump activity: a possible secondary mechanism in BrCCl3 and CCl4 liver cell injury. Adv Exp Med Biol. 1981;136 Pt A:619–31. Epub 1981/01/01.
- 43. Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol. 2008;73(2):399–409. Epub 2007/11/17. pmid:18006644
- 44. Fudge NJ, Kovacs CS. Physiological studies in heterozygous calcium sensing receptor (CaSR) gene-ablated mice confirm that the CaSR regulates calcitonin release in vivo. BMC Physiol. 2004;4:5. Epub 2004/04/22. PubMed Central PMCID: PMC419359. pmid:15099400
- 45. Knockaert L, Berson A, Ribault C, Prost PE, Fautrel A, Pajaud J, et al. Carbon tetrachloride-mediated lipid peroxidation induces early mitochondrial alterations in mouse liver. Lab Invest. 2012;92(3):396–410. Epub 2011/12/14. pmid:22157718